Enterprise Value
70.4M
Cash
24.86M
Avg Qtr Burn
-4.622M
Short % of Float
0.67%
Insider Ownership
2.92%
Institutional Own.
12.77%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MAT2203 (oral and non-toxic encochleated form of amphotericin B (CAmB)) Details Meningitis, Cryptococcal meningitis | Phase 3 Data readout | |
LYPDISO (MAT9001) (Omega-3 Drug) Details Cardiovascular disease | Failed Discontinued |